Przejdź do zawartości
Merck

Feasibility study of brain tumor delineation using immunolabeled gold nanorods.

Biomedical optics express (2013-12-04)
Kevin Seekell, Spencer Lewis, Christy Wilson, Shuqin Li, Gerald Grant, Adam Wax
ABSTRAKT

Effective treatment of patients with malignant brain tumors requires surgical resection of a high percentage of the bulk tumor. Surgeons require a method that enables delineation of tumor margins, which are not visually distinct by eye. In this study, the feasibility of using gold nanorods (GNRs) for this purpose is evaluated. Anti-Epidermal Growth Factor Receptor (anti-EGFR) conjugated GNRs are used to label human xenograft glioblastoma multiforme (GBM) tumors embedded within slices of brain tissues from healthy nude mice. The anti-EGFR GNRs exhibit enhanced absorption at red to near-infrared wavelengths, often referred to as the tissue optical window, where absorption from blood is minimal. To enable definition of molecular specificity and spatial accuracy of the label, the GNR absorption is compared with GFP fluorescence which is expressed by the GBM cells used here. This work demonstrates a simple but highly translational technique to classify normal and malignant brain tissue regions in open surgery applications using immunolabeled GNR contrast agents.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Anti-EGF Receptor antibody, Mouse monoclonal, clone 225, purified from hybridoma cell culture
Sigma-Aldrich
Gold(III) chloride trihydrate, ≥99.9% trace metals basis